May only be prescribed by Drug Addiction Treatment Act-certified prescribers
FRIDAY, June 15, 2018 (HealthDay News) — The first generic version of an under-the-tongue film to treat opioid addiction has been approved by the U.S. Food and Drug Administration.
The generic version of Suboxone (buprenorphine and naloxone) film from Mylan Technologies Inc. and Dr. Reddy’s Laboratories SA will be available in different strengths.
The brand name and generic films should be used as part of an overall treatment plan that includes counseling and psychosocial support, and may only be prescribed by Drug Addiction Treatment Act-certified prescribers, the FDA said.
Common side effects of these films include numbness, burning and inflammation in the mouth, headache, nausea, vomiting, excessive sweating, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.
Most Speakers at FDA Advisory Committee Meetings Support Drug Approval 
Countries Involved in U.S. Clinical Trials Do Not Gain Timely Access to Approved Medicines 
FDA Suspends U.S. License of Chikungunya Vaccine 
Nearly 3 in 4 Older Adults Express Interest in Vaccine to Prevent Dementia 
Updated COVID-19 Shot Beneficial for Those With Autoimmune Rheumatic Disease 
AAP Issues Recommendations for Pediatric RSV Vaccination in 2026-2027 Season 
Trends Reported in Vaccination Coverage for Adolescents for 2025 
.jpg)
